Source comparison
CJC-1295 Safe According to Studies: Comparison
The table below compares CJC-1295 safety data against other peptides in the GHRH and ghrelin mimetic categories based on published clinical trial evidence. CJC-1295 (DAC) 12 weeks Injection site reactions (38–40%), mild headache (10–15%), transient edema (14%)
This comparison does not assign a generated winner or score.
- The table below compares CJC-1295 safety data against other peptides in the GHRH and ghrelin mimetic categories based on published clinical trial evidence.
- CJC-1295 (DAC)
- 12 weeks
- Injection site reactions (38–40%), mild headache (10–15%), transient edema (14%)
- None in published trials
- Research use only. No FDA approval
- Favorable short-term safety; long-term data absent
- CJC-1295 (no DAC / Mod GRF 1-29)
- 28 days
- Injection site reactions (30–35%), flushing (12%)
- None reported
- Minimal adverse events; very short observation windows
- Tesamorelin (GHRH analog, FDA-approved)
- 52 weeks (HIV lipodystrophy trials)
- Injection site reactions (30%), arthralgias (14%), peripheral edema (9%)
- Rare: hyperglycemia in diabetic patients
- FDA-approved for HIV-associated lipodystrophy
- Only GHRH analog with >1 year human data and regulatory approval
- Ipamorelin (ghrelin mimetic)
- 7 days
- Mild nausea (8%), injection site pain (15%)
- None in published studies
- Research use only
- Extremely limited human data. Mostly animal studies
- MK-677 (oral ghrelin mimetic)
- 24 months
- Increased appetite (42%), mild edema (18%), elevated fasting glucose (12%)
- Rare: worsening of pre-existing heart failure
- No FDA approval for non-frailty indications
- Longest observation period of any GH secretagogue; glucose impact notable
- The key takeaway: CJC-1295 safe according to studies holds for observation periods under 90 days, but it lacks the multi-year safety surveillance that FDA-approved peptides like tesamorelin have undergone. Tesamorelin trials in over 800 HIV patients tracked adverse events for 52+ weeks, revealing tolerability comparable to CJC-1295 but with documented glucose monitoring protocols for diabetic patients. A detail absent from CJC-1295 studies.